NCT02117687

A Safety and Efficacy Study of OPTIVE FUSION™ With VISMED® Multi for the Management of Dry Eye

• Status: Completed
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 80 (actual)
• Sponsor: Allergan · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This study will evaluate the safety and efficacy of OPTIVE FUSION™ compared to VISMED® Multi for the management of dry eye.

Conditions

• Dry Eye Syndromes
• Keratoconjunctivitis Sicca

Interventions

Type	Name	Description
DRUG	carboxymethylcellulose 0.5%/glycerin 0.9%	1-2 drops OPTIVE FUSION™ (carboxymethylcellulose 0.5%/glycerin 0.9%) in each eye as needed at least 2 times and no more than 6 times daily, for 3 months.
DRUG	sodium hyaluronate 0.18%	1-2 drops VISMED® Multi (sodium hyaluronate 0.18%) in each eye as needed at least 2 times and no more than 6 times daily, for 3 months.

Timeline

• Start date: 2014-05-14
• Primary completion: 2015-01-27
• Completion: 2015-03-17
• First posted: 2014-04-21
• Last updated: 2019-04-18
• Results posted: 2016-02-19

Locations

2 sites across 2 countries: France, United Kingdom